<DOC>
	<DOCNO>NCT03027973</DOCNO>
	<brief_summary>This study compare two treatment management heavy menstrual bleeding , ulipristal acetate ( UPA ) tranexamic acid ( TEA ) , health-related quality life . Half participant receive UPA placebo , half receive TEA placebo .</brief_summary>
	<brief_title>Quality Life Outcomes Ulipristal Acetate Tranexamic Acid Management Heavy Menstrual Bleeding</brief_title>
	<detailed_description>UPA approve Health Canada treatment sign symptom uterine fibroid adult woman reproductive age eligible surgery . UPA consider investigational study , approve Health Canada treatment heavy menstrual bleed woman uterine fibroid . TEA approve Health Canada prevention reduction bleed different condition , include heavy period . This treatment available part routine care regular heavy menstrual bleeding use comparison treatment study .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Menorrhagia</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>Participants female uterus Participants age 18 51 year time consent Participants heavy menstrual bleeding evidence symptom subjective increase bleeding volume desire seek treatment The symptom heavy menstrual bleeding present last 6 month Participants regular menstrual cycle 24 38 day length Participants pregnant positive urine Î²hCG Participants whose bleed come cervical , vaginal , urinary gastrointestinal source Participants find previous diagnosis uterine cervical polyp , adenomyosis , leiomyoma ( fibroid ) Participants find endometrial hyperplasia , cervical dysplasia malignancy vulva , cervix , endometrium , breast ovary . Participants ovulatory dysfunction define menstrual cycle irregular frequency regularity often punctuate period amenorrhea Participants find diagnose coagulopathy Participants current genitourinary infection Participants desirous become pregnant within next four month Participants untreated inadequately treat thyroid disease Participants contraindication either treatment include hypersensitivity Participants breastfeed Participants mild , moderate severe hepatic impairment Participants moderate severe renal impairment Participants severe asthma controlled oral glucocorticoid Participants active disease , history deep vein thrombosis ( DVT ) , pulmonary embolism ( PE ) , cerebral thrombosis family history thromboembolic disease Patients subarachnoid hemorrhage Patients acquire disturbance colour vision Participants already hormone base treatment include , progesterone pill , combine oral contraceptive pill ( COCP ) , Intrauterine System ( IUS )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>51 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>